痛泻要方联合匹维溴铵治疗腹泻型肠易激综合征临床研究

目的 观察痛泻要方联合匹维溴铵治疗腹泻型肠易激综合征的临床疗效。方法 收集280例腹泻型肠易激综合症患者，每组70人，分为4组：初治试验组、初治对照组、复治试验组、复治对照组。初治试验组和复治试验组给予痛泻要方和匹维溴铵，初治对照组和复治对照组给予匹维溴铵。4组疗程都为4周，观察治疗前后症状总积分和疗效。结果 治疗后4组症状总积分较治疗前均有显著降低（P<0.05）。复治对照组治疗前后症状总积分差值显著小于初治对照组和复治试验组（P<0.05）。初治组和复治组之间的临床疗效差异无统计学意义（P>0.05），对照组和试验组之间的临床疗效差异有统计学意义（P<0.05），复治试验组和复治对照组之间的临床疗效差异也有统计学意义（P<0.05）。结论 痛泻要方联合匹维溴铵可提高腹泻型肠易激综合征的疗效，在有过相关药物治疗史的复治患者中疗效尤为明显。

Clinical Efficacy of Tongxieyaofang Combined with Pinaverium Bromide in Treatment of Diarrhea-predominant Irritable Bowel Syndrome

Objective To investigate the clinical efficacy of Tongxieyaofang combined with pinaverium bromide in the treatment of diarrhea-predominant irritable bowel syndrome. Methods A total of 280 patients with diarrhea-predominant irritable bowel syndrome were enrolled and divided into previously untreated trial group, previously untreated control group, previously treated trial group, and previously treated control group, with 70 in each group. The patients in the previously untreated trial group and the previously treated trial group were given Tongxieyaofang and pinaverium bromide, and those in the previously untreated control group and the previously treated control group were given pinaverium bromide. The course of treatment was 4 weeks for all groups. The total symptom scores before and after treatment and therapeutic efficacy were observed. Results All the groups showed significant reductions in the total symptom score after treatment (P<0.05 ). Compared with the previously untreated control group and previously treated trial group, the previously treated control group showed a significantly smaller change in the total symptom score after treatment (P<0.05). The clinical efficacy showed no significant difference between previously untreated groups and previously treated groups (P>0.05), but showed a significant difference between control groups and trial groups (P<0.05), particularly between the previously treated trial group and the previously treated control group (P<0.05). Conclusion Tongxieyaofang combined with pinaverium bromide can improve the outcome of diarrhea-predominant irritable bowel syndrome, particularly in patients previously treated with related drugs.